ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DPH Dechra Pharmaceuticals Plc

3,866.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3,866.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Delphi To Terminate Methode Contract Next Week

03/09/2009 12:57pm

Dow Jones News


Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Dechra Pharmaceuticals Charts.

Methode Electronics Inc. (MEI) said Delphi Corp. (DPHIQ) has told the company it will terminate its supply deal with Methode in one week.

The move is the latest battle between the companies - Methode in April filed a patent-infringement suit against Delphi contending it owns the technology for a sensing device built by Methode, a Delphi supplier and maker of electromechanical devices.

Delphi has contended in court documents that it was pushed into accepting a 40% price increase from Methode last year, according to Automotive News. It wants control of tooling drawings, which would enable it to move the work to another supplier.

Delphi has been under bankruptcy protection for several years and has been struggling to find the necessary financing to leave court.

Meanwhile, Methode reported a fiscal first-quarter loss of $19,000, compared with a prior-year profit of $6.8 million, or 16 cents a share. The results included restructuring charges of 10 cents and 9 cents, respectively. The company has been moving to lessen its exposure to the beaten-down North American auto industry, including stopping to provide products to Ford Motor Co. (F) in the region and Chrysler Group LLC.

Revenue slumped one-third to $89.8 million.

Gross margin dipped to 21% from 21.6%.

Methode shares closed Wednesday at $8.31 and were inactive premarket. The stock is up 23% this year.

-By Kevin Kingsbury, Dow Jones Newswires; 212-416-2354; kevin.kingsbury@dowjones.com

 
 

1 Year Dechra Pharmaceuticals Chart

1 Year Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart